Which patients with estrogen receptor-positive early breast cancer should be treated with adjuvant chemotherapy?

Vincenzo Emanuele Chiuri, Vito Lorusso

Research output: Contribution to journalArticle

Abstract

Estrogen receptor expression in breast cancer cells represents an important predictive and prognostic factor. The estrogen receptor is a target for endocrine therapy, which avoids chemotherapy especially in highly hormone-sensitive early breast cancer. Paradoxically, recent data from several clinical trials and meta-analyses have demonstrated the superiority of adjuvant chemotherapy independently of age, estrogen receptor and nodal status. For this reason, new tools are needed to better define the intrinsic characteristics of breast cancers and to establish the role of cytotoxic treatment for those tumors with potentially good outcome, such as hormone-sensitive early breast cancer.

Original languageEnglish
Pages (from-to)18-22
Number of pages5
JournalOncology
Volume77
Issue numberSUPPL. 1
DOIs
Publication statusPublished - Feb 2010

Fingerprint

Adjuvant Chemotherapy
Estrogen Receptors
Breast Neoplasms
Hormones
Meta-Analysis
Clinical Trials
Drug Therapy
Therapeutics
Neoplasms

Keywords

  • Chemotherapy
  • Early breast cancer
  • Estrogen receptor
  • HER2
  • Hormone therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Which patients with estrogen receptor-positive early breast cancer should be treated with adjuvant chemotherapy? / Chiuri, Vincenzo Emanuele; Lorusso, Vito.

In: Oncology, Vol. 77, No. SUPPL. 1, 02.2010, p. 18-22.

Research output: Contribution to journalArticle

@article{d1463237681f4c46901198bdf91e6a43,
title = "Which patients with estrogen receptor-positive early breast cancer should be treated with adjuvant chemotherapy?",
abstract = "Estrogen receptor expression in breast cancer cells represents an important predictive and prognostic factor. The estrogen receptor is a target for endocrine therapy, which avoids chemotherapy especially in highly hormone-sensitive early breast cancer. Paradoxically, recent data from several clinical trials and meta-analyses have demonstrated the superiority of adjuvant chemotherapy independently of age, estrogen receptor and nodal status. For this reason, new tools are needed to better define the intrinsic characteristics of breast cancers and to establish the role of cytotoxic treatment for those tumors with potentially good outcome, such as hormone-sensitive early breast cancer.",
keywords = "Chemotherapy, Early breast cancer, Estrogen receptor, HER2, Hormone therapy",
author = "Chiuri, {Vincenzo Emanuele} and Vito Lorusso",
year = "2010",
month = "2",
doi = "10.1159/000258492",
language = "English",
volume = "77",
pages = "18--22",
journal = "Oncology",
issn = "0030-2414",
publisher = "UBM Medica Healthcare Publications",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Which patients with estrogen receptor-positive early breast cancer should be treated with adjuvant chemotherapy?

AU - Chiuri, Vincenzo Emanuele

AU - Lorusso, Vito

PY - 2010/2

Y1 - 2010/2

N2 - Estrogen receptor expression in breast cancer cells represents an important predictive and prognostic factor. The estrogen receptor is a target for endocrine therapy, which avoids chemotherapy especially in highly hormone-sensitive early breast cancer. Paradoxically, recent data from several clinical trials and meta-analyses have demonstrated the superiority of adjuvant chemotherapy independently of age, estrogen receptor and nodal status. For this reason, new tools are needed to better define the intrinsic characteristics of breast cancers and to establish the role of cytotoxic treatment for those tumors with potentially good outcome, such as hormone-sensitive early breast cancer.

AB - Estrogen receptor expression in breast cancer cells represents an important predictive and prognostic factor. The estrogen receptor is a target for endocrine therapy, which avoids chemotherapy especially in highly hormone-sensitive early breast cancer. Paradoxically, recent data from several clinical trials and meta-analyses have demonstrated the superiority of adjuvant chemotherapy independently of age, estrogen receptor and nodal status. For this reason, new tools are needed to better define the intrinsic characteristics of breast cancers and to establish the role of cytotoxic treatment for those tumors with potentially good outcome, such as hormone-sensitive early breast cancer.

KW - Chemotherapy

KW - Early breast cancer

KW - Estrogen receptor

KW - HER2

KW - Hormone therapy

UR - http://www.scopus.com/inward/record.url?scp=77949908159&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949908159&partnerID=8YFLogxK

U2 - 10.1159/000258492

DO - 10.1159/000258492

M3 - Article

VL - 77

SP - 18

EP - 22

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - SUPPL. 1

ER -